Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Sep 24, 2022 5:02pm
175 Views
Post# 34984458

RE:RE:RE:RE:Thera continues to post on cancer on Linkedin

RE:RE:RE:RE:Thera continues to post on cancer on Linkedin

To be more sober, I think they should always be preparing for success whether it's going to come or not. Assuming there is still a lot of recruitment still to happen and that many of the recruited will only have recieved a few cycles there's not really anything that could be too negative at this point in time other than a big horrible safety issue revealing itself. So right now I'm fairly neutral on whether they have actually have something super positive bin hand or whether they are just moving forward with the assumption that it will come.

The program is alive until it's not. They are in the oncology space, why would you not post about oncology? 


TH1902 wrote: So JFM are you implying that you believe TH1902 1b will be successful based on this?

I also find it curious and reading through SPCEO's last long note, many reasons to think that something positive is about to happen.

Hope you are doing ok.
 

jfm1330 wrote: When they were actively pushing NASH, it was not during an ongoing open label clinical trial.

SABBOBCAT wrote: Remember when the company used to post about NASH and go to conference to talk it up? Good times LOL. In al seriousness I do think this time is finally different, but I think Mr Market has it right with the "I'll believe it when I see it" approach.

 




<< Previous
Bullboard Posts
Next >>